Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

November 3, 2017: By Joan McKenna


Allergan told analysts Nov. 1 that it is taking several steps to prepare for loss of patent exclusivity for Restasis in 2018, even as net sales of its dry eye treatment increased 2.9 percent in Q3-2017 year over year.

Allergan CEO Brent Saunders said the move followed a recent US district court decision that invalidated four of Restasis’ patents. The company has appealed the decision.

Dublin-based Allergan has taken impairment charges of $3.2 billion related to Restasis and $164.0 million related to other dry eye assets obtained in its acquisition of legacy Allergan.

In addition, the company is making plans to reduce costs, while protecting long-term growth drivers, as it prepares for possible scenarios, including a Restasis generic launching Jan. 1, 2018, or one launching in mid-2018. The FDA currently has not approved a generic version.

Saunders said those cost reductions will be implemented rapidly as soon as officials complete their planning. Still, the company intends to increase its dividend and pay down nearly $4 billion in debt in Q1-2018.

Allergan’s net revenues in Q3-2017 totaled $4.03 billion, an 11 percent increase over the same quarter in 2016.

Officials noted that the company is committed to eye care, which is a $2 billion annual business without Restasis.

Other ophthalmic products that performed well in the third quarter included Ozurdex, an implant for diabetic macular edema and other retinal conditions. Net revenues increased 17.7 percent in the US to $24.6 million and 12 percent outside the US to $50.2 million, due to increasing demand.

Restasis’ net revenues in the third quarter totaled $366.8 million. Full-year revenues are expected to total about $1.4 billion.

Asked about competition from compounding pharmacies, Saunders said Allergan would watch the situation closely, ensuring that compounders are not allowed to find an alternative path to launching drugs without the full oversight and review that the FDA has for medicines.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022